Research and Markets (http://www.researchandmarkets.com/research/l79xgn/nexgenerix) has announced the addition of the "NexGenerix" report to their offering.
The only one-stop source for business critical information on 79 new chemical entities set to become generics between 2016 to 2026.
The report provides precise information on patent expiry, patent expiry extensions, special protection certificate, first market authorization, all market authorizations, orphan and pediatric drug exclusivity and much more in 34 countries around the world.
What: Patent and market research database for generic drugs
When: 77 NCEs due for generic launch between years 2016 to 20
Where: Covers 37 countries including US, EU and Japan
Why: Best-in-class value, up-to-date
Who: Business decision makers in the pharmaceutical industry
Key Topics Covered:
1. Highlights
2. Patents
- Patent Expiry Extension (34 countries):
- Patent Term Extension/US
- Supplementary Protection Certificate/signatories countries
3. Extension of Supplementary Protection Certificate (Pediatric drugs)
- Patent extension/other national markets
- Patent Expiry (34 countries)
- NCE patent priority and filing dates
- Expiry dates
- Ownership, developer/licensee
- Indication
- Direct access to patent claims, synopsis, citations and full text
4. Markets
- First market authorization date (North America / EU / Japan)
- Market term extension (North America / EU / Japan)
- Orphan drug exclusivity (ODE) (US)
- Pediatric drugs exclusivity (PDE) (US)
5. Other information
- Paragraph IV patent challenge (US)
- Dosage forms (North America, Japan, UK and France)
- Drug substance COS/DMF
- Indication
- Global sales by product
7. Information filters
For more information visit http://www.researchandmarkets.com/research/l79xgn/nexgenerix
